Literature DB >> 25205644

Adaptive choice of patient subgroup for comparing two treatments.

Tze Leung Lai1, Philip W Lavori2, Olivia Yueh-Wen Liao3.   

Abstract

This paper is motivated by a randomized controlled trial to compare an endovascular procedure with conventional medical treatment for stroke patients, in which the endovascular procedure may be effective only in a subgroup of patients. Since the subgroup is not known at the design stage but can be learned statistically from the data collected during the course of the trial, we develop a novel group sequential design that incorporates adaptive choice of the patient subgroup among several possibilities which include the entire patient population as a choice. We define the type I and type II errors of a test in this design and show how a prescribed type I error can be maintained by using the closed testing principle in multiple testing. We also show how asymptotically optimal tests can be constructed by using generalized likelihood ratio statistics for parametric problems and analogous standardized or Studentized statistics for nonparametric tests such as Wilcoxon's rank sum test commonly used for treatment comparison in stroke patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adaptive selection; Generalized likelihood ratio statistics; Group sequential design; Kullback–Leibler information; Multiple testing; Normalized Wilcoxon statistic

Mesh:

Substances:

Year:  2014        PMID: 25205644      PMCID: PMC4470707          DOI: 10.1016/j.cct.2014.09.001

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  7 in total

1.  Closed testing procedures for group sequential clinical trials with multiple endpoints.

Authors:  D I Tang; N L Geller
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

2.  Mid-course sample size modification in clinical trials based on the observed treatment effect.

Authors:  Christopher Jennison; Bruce W Turnbull
Journal:  Stat Med       Date:  2003-03-30       Impact factor: 2.373

3.  Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations.

Authors:  Christopher Jenniso; Bruce W Turnbull
Journal:  Biom J       Date:  2006-08       Impact factor: 2.207

4.  Efficient adaptive designs with mid-course sample size adjustment in clinical trials.

Authors:  Jay Bartroff; Tze Leung Lai
Journal:  Stat Med       Date:  2008-05-10       Impact factor: 2.373

5.  Optimal Tests of Treatment Effects for the Overall Population and Two Subpopulations in Randomized Trials, using Sparse Linear Programming.

Authors:  Michael Rosenblum; Han Liu; En-Hsu Yen
Journal:  J Am Stat Assoc       Date:  2014-01-01       Impact factor: 5.033

6.  Adaptive enrichment designs for clinical trials.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2013-03-21       Impact factor: 5.899

7.  Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience.

Authors:  Sharon D Yeatts; Renee H Martin; Christopher S Coffey; Patrick D Lyden; Lydia D Foster; Robert F Woolson; Joseph P Broderick; Marco R Di Tullio; Charles A Jungreis; Yuko Y Palesch
Journal:  Stroke       Date:  2014-04-03       Impact factor: 7.914

  7 in total
  9 in total

1.  Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging.

Authors:  Gregory W Albers; Michael P Marks; Stephanie Kemp; Soren Christensen; Jenny P Tsai; Santiago Ortega-Gutierrez; Ryan A McTaggart; Michel T Torbey; May Kim-Tenser; Thabele Leslie-Mazwi; Amrou Sarraj; Scott E Kasner; Sameer A Ansari; Sharon D Yeatts; Scott Hamilton; Michael Mlynash; Jeremy J Heit; Greg Zaharchuk; Sun Kim; Janice Carrozzella; Yuko Y Palesch; Andrew M Demchuk; Roland Bammer; Philip W Lavori; Joseph P Broderick; Maarten G Lansberg
Journal:  N Engl J Med       Date:  2018-01-24       Impact factor: 91.245

2.  Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data.

Authors:  Maarten G Lansberg; Ninad S Bhat; Sharon D Yeatts; Yuko Y Palesch; Joseph P Broderick; Gregory W Albers; Tze L Lai; Philip W Lavori
Journal:  Stroke       Date:  2016-11-15       Impact factor: 7.914

3.  A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3).

Authors:  Gregory W Albers; Maarten G Lansberg; Stephanie Kemp; Jenny P Tsai; Phil Lavori; Soren Christensen; Michael Mlynash; Sun Kim; Scott Hamilton; Sharon D Yeatts; Yuko Palesch; Roland Bammer; Joe Broderick; Michael P Marks
Journal:  Int J Stroke       Date:  2017-03-24       Impact factor: 5.266

4.  Adaptive design of confirmatory trials: Advances and challenges.

Authors:  Tze Leung Lai; Philip W Lavori; Ka Wai Tsang
Journal:  Contemp Clin Trials       Date:  2015-06-14       Impact factor: 2.226

5.  Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.

Authors:  Neha Joshi; Jason Fine; Rong Chu; Anastasia Ivanova
Journal:  J Biopharm Stat       Date:  2019-07-04       Impact factor: 1.051

6.  The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.

Authors:  Anastasia Ivanova; Elliot Israel; Lisa M LaVange; Michael C Peters; Loren C Denlinger; Wendy C Moore; Leonard B Bacharier; M Alison Marquis; Nathan M Gotman; Michael R Kosorok; Chalmer Tomlinson; David T Mauger; Steve N Georas; Rosalind J Wright; Patricia Noel; Gary L Rosner; Praveen Akuthota; Dean Billheimer; Eugene R Bleecker; Juan Carlos Cardet; Mario Castro; Emily A DiMango; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin M Gaston; Fernando Holguin; Sonia Jain; Nicholas J Kenyon; Jerry A Krishnan; Monica Kraft; Rajesh Kumar; Mark C Liu; Ngoc P Ly; James N Moy; Wanda Phipatanakul; Kristie Ross; Lewis J Smith; Stanley J Szefler; W Gerald Teague; Michael E Wechsler; Sally E Wenzel; Steven R White
Journal:  J Biopharm Stat       Date:  2020-09-17       Impact factor: 1.051

7.  Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.

Authors:  Ting Wang; Xiaofei Wang; Stephen L George; Haibo Zhou
Journal:  J Biopharm Stat       Date:  2020-11-11       Impact factor: 1.051

8.  Multi-stage adaptive enrichment trial design with subgroup estimation.

Authors:  Neha Joshi; Crystal Nguyen; Anastasia Ivanova
Journal:  J Biopharm Stat       Date:  2020-10-18       Impact factor: 1.051

9.  Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.

Authors:  Louis Jacob; Maria Uvarova; Sandrine Boulet; Inva Begaj; Sylvie Chevret
Journal:  BMC Med Res Methodol       Date:  2016-06-02       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.